- Home
- NUV vs NRIX Comparison
NUV vs NRIX Comparison
Compare NUV & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUV | NRIX |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NUV | NRIX |
|---|---|---|
| Price | $9.13 | $18.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 464.9K | ★ 1.5M |
| Earning Date | 01-01-0001 | 10-09-2025 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $83,687,000.00 |
| Revenue This Year | N/A | $58.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 48.32 |
| 52 Week Low | $7.86 | $8.18 |
| 52 Week High | $9.08 | $22.95 |
Technical Indicators
Market Signals| Indicator | NUV | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 59.98 | 74.27 |
| Support Level | $9.03 | $16.02 |
| Resistance Level | $9.09 | $17.79 |
| Average True Range (ATR) | 0.05 | 1.10 |
| MACD | 0.00 | 0.16 |
| Stochastic Oscillator | 92.86 | 96.84 |
Price Performance
Historical ComparisonAbout NUV Nuveen Municipal Value Fund Inc.
Nuveen Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.